How effective is clofazimine in treating tuberculosis?

Clofazimine (Clofazimine) is an oral antibiotic with antibacterial and anti-inflammatory effects. It was first used to treatleprosy. In recent years, it has been re-incorporated into the treatment of drug-resistant tuberculosis due to its unique pharmacological properties. As cases of multidrug-resistant and extensively drug-resistant tuberculosis (MDR-TB and XDR-TB) continue to rise, clofazimine has gradually shown potential advantages in combination treatment regimens. Its mechanism of action mainly interferes with replication by embedding into bacterial DNA and destroying the cell membrane, thereby exerting a bactericidal effect and showing certain in vitro inhibitory activity against Mycobacterium tuberculosis.

In the treatment of pulmonary tuberculosis, clofazimine is not used as a first-line drug, but is mostly used in the second-line treatment combination of refractory or drug-resistant tuberculosis, especially when standard anti-tuberculosis drugs are ineffective or intolerable. It is often used in combination with bedaquiline, linezolid, prothionamide and other drugs to construct a personalized anti-tuberculosis program. Its pharmacokinetic properties are also special. It is highly lipid-soluble and easy to accumulate in lung tissue and immune cells, allowing it to exhibit a long-lasting effect in sustained bactericidal effects. Due to the long half-life of clofazimine, its residual concentration in the body can still maintain a certain therapeutic effect even if the drug is stopped midway. This feature may have additional advantages in the control of chronic pulmonary infections.

However, clofazimine's use in treating tuberculosis is not without controversy. Some studies have pointed out that its anti-tuberculosis efficacy is limited by blood concentration and the ability to target intracellular lesions, so it usually needs to be combined with other drugs to enhance its efficacy. In addition, long-term use may cause skin pigmentation and gastrointestinal side effects, which is also one of the considerations that need to be weighed in clinical use. Currently, the tuberculosis management guidelines of the World Health Organization and many countries have gradually included clofazimine as one of the recommended drug sequences for drug-resistant pulmonary tuberculosis, indicating that its therapeutic status in specific patient groups is gradually recognized.

Reference materials:https://www.novartis.com/our-products/pipeline/clofazimine